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we summarize and discuss the knowledge gained in the recent years on the molecular mechanisms of TDP-43 
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Introduction
The identification of mutations in RNA binding proteins 
(RBPs) leading to an enhanced risk of developing neurological dis-
eases has surged in the past decade. Such diseases encompass a 
diverse group, including amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD),[1] spinocerebellar ataxia (SCA)[2] 
and multisystem proteinopathies (MSP).[3] A common hallmark of 
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The sequence-specific RNA binding[21a,24] of TDP-43 via its 
two RNA recognition motifs (RRMs)[25] mediates the interaction 
with over 6000 protein-coding RNA targets with high fidelity, 
which accounts for 30% of total murine transcriptome.[22] The 
majority of TDP-43 binding sites (60%) are located in long in-
tronic regions of neuronal genes and this binding is required for 
sustaining their normal levels.[22a] The extensive intronic binding 
of TDP-43 facilitates the repression of cryptic exons,[26] which are 
canonical exons that remain unused in physiological conditions. 
Cryptic exons often contain premature stop codons or polyadenyl-
ation sites that alter cellular RNA homeostasis and loss of TDP-43 
function in disease was shown to interfere with this.[26] An impor-
tant and disease-relevant example of this regulation is the TDP-43 
repression of a non-conserved cryptic polyadenylation site in the 
mRNA of the neuronal growth-associated factor stathmin-2, lead-
ing to the production of a truncated, non-functional mRNA that is 
devastating for neurons.[27]
The second most enriched TDP-43 binding sites (30%) are 
those near canonical intron-exon junctions where it modulates the 
alternative splicing of the respective flanking exons.[22a] In order 
to achieve this, TDP-43 acts in concert with other hnRNPs[21b] and 
can either enhance inclusion or exclusion of alternative exons de-
pending on the location of the binding site.[22a] TDP-43 also binds 
to many non-coding RNAs such as nuclear-enriched autosomal 
transcript 1 (NEAT1) and metastasis-associated lung adenocar-
cinoma transcript 1 (MALAT1), whose expression is elevated in 
FTD-TDP patients.[22b] Lastly, TDP-43 has been shown to pro-
mote miRNA biogenesis and shown to be part of the Drosha and 
Dicer complexes[28] and thereby regulates expression of several 
cancer associated miRNAs.[29]
Translational Regulation and Response to Stress
TDP-43 is primarily localized to the nucleus in a steady state, 
where it associates with its nucleic acid targets.[30] However, un-
der physiological conditions, TDP-43 actively shuttles between 
the nucleus and the cytoplasm, and a small percentage of the to-
tal cellular TDP-43 (up to 30%) can be found in the latter com-
partment,[31] where it associates with the 3'-UTR of its mature 
mRNA targets,[22b] thereby modulating their stability, localization 
and translation.[22a,32] Importantly, TDP-43 binds on the 3'-UTR 
of its own mRNA, to regulate its stability and translation,[22a,33] 
through a complex and finely controlled mechanism based on the 
combinatorial action of alternative splicing, polyadenylation site 
selection and translation.[32b,34] For other mRNA targets, TDP-43 
regulates either the mRNA stability, the transport, or the transla-
tion.[35] Proteomic studies have shown that TDP-43 interacts with 
proteins involved in translation initiation and subsequent elonga-
tion factors.[36] Moreover, TDP-43 may also control spatial trans-
lation by transporting mRNA to distal cellular sites such as axon 
terminals, thereby modulating local translation[37] and regulating 
of axon growth[37a] and potentially other functions.
Finally, the ability of TDP-43 to phase separate into liq-
uid droplets enables its recruitment into stress granules, which 
halt the translation of specific mRNAs during the cellular stress 
 response. [38] Both RNA binding and the low complexity region 
of TDP-43 are indispensable for its recruitment into stress gran-
ules.[38a] Regulation of stress granules dynamics via phase separa-
tion is an important area of interest due to the potential mechanistic 
similarity with the origin of pathologic aggregation[39] (discussed 
later). Before discussing the molecular mechanisms of pathologic 
aggregation, we first summarize which regions of TDP-43 confer 
specific above-mentioned functional roles to the protein. 
Structural Determinants of TDP-43 Function
The only human isoform of TDP-43 is the 414 amino acids 
(aa) long 43 kDa protein, although a smaller alternative cDNA 
of 298 aa has been reported but not proved to be expressed.[40] 
these diverse diseases are alterations in RNA metabolism, which 
result from loss of function due to protein mislocalization and from 
gain of toxic functions by the accumulated pathological protein 
aggregates.[4] A key protein involved in virtually all cases of ALS 
and various forms of FTD is TAR (transactivation response) DNA 
binding protein of 43 kDa (TDP-43).[4a,5] TDP-43 structurally be-
longs to a family of heterogeneous ribonucleoproteins (hnRNPs) 
and is primarily localized to the nucleus.[6] Neurological disorders 
linked to TDP-43 pathology are classified as TDP-43 proteino-
pathies,[1,5] and are characterized by nuclear clearance of TDP-43 
and cytoplasmic TDP-43-positive inclusions that display charac-
teristic pathological features such as ubiquitination, fragmentation 
and hyperphosphorylation.[1,5] Most cases with TDP-43 pathology 
are sporadic, therefore lacking family history.[7] Familial ALS cas-
es due to mutations in TDP-43 are rare[8] and they also show the 
presence of cytoplasmic TDP-43-positive inclusions. Intriguingly, 
TDP-43-positive inclusions are also found in familial ALS linked 
to genetic mutations in proteins involved in degradation pathways 
such as UBQLN2,[9] SQSTM1,[10] VCP[11] and OPTN.[12] Why and 
how these mutations result in TDP-43 aggregation still remains elu-
sive. Moreover, mutations in genes involved in RNA processing 
pathways, such as MATR3,[13] HNRNPA2B1,[14] HNRNPA1,[14] and 
C9ORF72[15] have been associated with TDP-43 proteinopathies. 
Therefore, different upstream alterations converge on TDP-43 ag-
gregation in various neurodegenerative diseases, making TDP-43 
an attractive target for both diagnosis and therapeutic interventions.
Here we review the structural determinants of TDP-43 func-
tion and dysfunction in health and disease. Based on various struc-
tural, biophysical, biochemical and in vivo data, we summarize 
our current understanding on the molecular mechanisms of TDP-
43 aggregation. A clear identification of the specific early events 
leading to TDP-43 misfolding or mislocalization is necessary for 
the development of preventive and disease-modifying therapeu-
tics. At the same time, a clear distinction between the functional 
and pathological states is key for early diagnosis and for monitor-
ing disease progression.
Physiological Functions of TDP-43 
Transcriptional Regulation
TDP-43 encoded from the TARDBP gene located on human 
chromosome 1 was first identified as a protein factor that binds to 
the regulatory transactivation response element (TAR) of human 
immunodeficiency virus type 1 (HIV-1) to repress transcription. [16] 
This binding gave TDP-43 its name (TAR DNA-binding protein 
of 43 kDa) but was later shown to be ineffective in altering the 
course of HIV-1 replication in human cells.[17] TDP-43 was also 
reported to act as a transcriptional repressor for the spermatid-
specific gene SP-10.[18] More recently, the binding of TDP-43 
to TG-rich sequences in the promoter region of ACRV1, another 
spermatid-specific gene, was found to repress its transcription in 
testis.[19] Moreover, TDP-43 is associated with transcriptionally-
enriched euchromatin in rat neurons and in human brain,[20] sug-
gesting broad roles in transcription control. 
RNA Metabolism
TDP-43 plays pleiotropic and important roles in RNA pro-
cessing, including regulation of alternative splicing, RNA matura-
tion, stability and trafficking. The first identified RNA target of 
TDP-43 is cystic fibrosis transmembrane conductance regulator 
(CFTR), whose alternative splicing is regulated by TDP-43 and 
other hnRNPs such as SR proteins.[21] However, the major role of 
TDP-43 in RNA metabolism emerged in subsequent years with 
the genome-wide identification of several hundred RNA targets 
in human and mouse brain.[22] Indeed, TDP-43 binds to numer-
ous nascent RNA transcripts, both pre-mRNAs and non-coding 
RNAs, to control their fate and function.[23]
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N-Terminal Domain Mediates Reversible TDP-43 
Polymerization
Shortly after the identification of TDP-43 as an aggregating 
protein in ALS and FTD, TDP-43 was shown to exist as dimers, 
which were suggested to act as seeds for pathologic inclusions in 
disease.[46] However, it was not clear which structural elements 
were involved in TDP-43 dimerization until the first reports on 
the involvement of TDP-43’s NTD in mediating oligomerization 
and increasing nucleic acid binding affinity.[47] The first high-res-
olution NMR structural models of the monomeric TDP-43 NTD 
suggested that this domain structurally resembled ubiquitin[48] 
and ubiquitin-like DIX[49] domains. The folded NTD (aa 1-80) 
was proposed to comprise of a stably folded β-sheet resulting 
from five anti-parallel β-strands that pack against an α-helix. [49] 
Additionally, one of the studies proposed that a nucleic acid- 
dependent equilibrium between the folded and unfolded state of 
the NTD may influence aggregation of TDP-43.[48] However, sev-
eral more recent studies, including those from single molecule 
Förster resonance energy transfer (smFRET), demonstrate that 
this domain is stably folded near physiological solution condi-
tions in vitro,[42,49,50] refuting the notion of such folded-unfolded 
equilibrium.
Most recently, the high-resolution crystal structure revealed 
the molecular basis of TDP-43 polymerization via its NTD (Fig. 
1). Together with cellular data, this structure showed the exis-
tence of functional oligomeric TDP-43 in physiological condi-
tions.[42] TDP-43 NTD forms head-to-tail interactions that al-
low the protein to oligomerize in association with nucleic acids 
Similar to numerous other hnRNPs,[41] TDP-43 has a modular 
multi-domain architecture comprising of an N-terminal domain 
(NTD), two RNA recognition motifs (RRMs) and a low com-
plexity region (LCR) in the C-terminal part of the protein (Fig. 
1). The N-terminal domain (NTD) and RRMs confer specific 
functional roles to the protein by mediating dynamic oligomer-
ization[42] and selection of specific RNA targets,[25] respectively. 
Additionally, TDP-43 harbours a bipartite nuclear localization 
signal (NLS)[30] and predicted nuclear export signals (NES)[43] al-
lowing the protein to shuttle between the nucleus and cytosol. [30] 
The TDP-43 NLS is located in the linker region between the 
NTD and the RRMs and is comprised of a stretch of basic aa 
(82KRKMDETDASSAVKVKR).[30] Two putative exportin-1/
CRM1-dependent NES sequences have been predicted for TDP-
43, both localized within its RRM2: 238IAQSLCGEDLII[31,43] and 
222IPKPFRAFAF.[44] However, neither of the two NES sequences 
are functional, and a recent study conclusively showed that TDP-
43 leaves the nucleus by passive diffusion,[44] similarly to other 
RNA-binding proteins linked to ALS like FUS.[45]
The complete three-dimensional structure of full length TDP-
43 remains to be resolved due to challenges in stability and solu-
bility of protein samples required for biophysical and structural 
analysis. Nevertheless, high-resolution structures of individual 
domains complemented with cellular assays have resulted in 
models of TDP-43 that explain some of its functional properties 
and potential transitions to the pathological state. Here, we brief-
ly summarize our existing knowledge gained from structural and 
biochemical studies using truncated TDP-43 domains.
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Fig. 1. Structure and domain organization of TDP-43. Schematic of modular domain organization of TDP-43 showing the N-terminal domain, RNA 
recognition motifs and low complexity region in blue, grey and red colors, respectively. TDP-43 forms oligomers mediated by interactions among the 
N-terminal domains of adjacent TDP-43 molecules (shown in cyan). Known high-resolution structures of the corresponding regions of TDP-43 are 
shown below the schematic (Protein Data Bank 1D – 5MDI for NTD[42], 4BS2 for RRMs[25] and 2N3X for low complexity region[59c]). Mutations identi-
fied in the familial cases of ALS and FTD cluster mainly in the low complexity region and are depicted on the corresponding TDP-43 schematic. 
ALS mutations are color-coded based on the protein domain that they are localized (blue for NTD, grey for RRM1 and red for LCR), except for those 
that fall into the LCR helical structure (braun),[59c] the reported steric zippers (purple)[61] or LARKS (orange).[61] The structures of the steric zippers and 
LARKS are not shown.
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nuclear inclusions that can be disaggregated by HSF-1 dependent 
chaperone.[57] Further PTMs close to RNA binding interface in-
fluencing RNA interactions are phosphorylations at Thr153 and 
Tyr155 by MEK in response to stress (Fig. 2).[58] In fact, upon 
heat shock, this phosphorylated TDP-43 (pTDP-43) is specifi-
cally recruited to nucleoli and forms inclusions that are distinct 
from the pTDP-43 described in ALS/FTD patients.[58]
Structure and Role of TDP-43 Low Complexity Region 
The C-terminal region of TDP-43 (aa 261-414) is a low com-
plexity glycine-rich region that, isolated in solution, is primarily 
unstructured but contains a short α-helix (aa 311-347) (Fig. 1).[59] 
TDP-43 LCRs have been reported to interact transiently via this 
α-helix,[59c] which has been proposed to also interact with mem-
branes, implying its potential in disrupting plasma membranes 
and other organelles like Aβ.[59b] Adjacent to this α-helix is a Q/N- 
rich sequence that has been suggested to form amyloidogenic 
cross β-sheet structures showing a unique X-ray fiber diffraction 
pattern distinct from other amyloids.[60] More recently, multiple 
short segments of the TDP-43 LCR were shown to form either ste-
ric zippers or reversible amyloid-like structures termed LARKS 
(low-complexity aromatic-rich kinked segments) in vitro,[61] sug-
gesting that this region may form complex and heterogeneous as-
semblies in cells. 
TDP-43 LCR has multifaceted functions and has been pro-
posed to mediate protein–protein and potentially stabilize pro-
tein–RNA interactions and is essential for TDP-43 splicing activ-
ity.[21b,24] Similar to other hnRNPs like FUS,[62] the 293RGG motif 
of TDP-43 LCR may modulate its affinity for target RNAs.[63] 
Indeed, arginine methylation in this motif may alter TDP-43 RNA 
interactions and enhance aggregation (Fig. 2).[64] Moreover, TDP-
43 interacts with another splicing factor hnRNAP A1 via the re-
gion of LCR localized (321-366) in the α-helix,[21b] where three 
reported steric zipper segments are also localized.[61]
Importantly, the LCR of TDP-43 can phase separate into liq-
uid droplets that potentially allows an increase in its local con-
centration at specific locations inside the cells.[38b,39a,59c,65] Phase 
separation has been suggested as an initial event leading to the 
formation of membrane-less organelles,[39a,65a,66] such as stress 
granules, via the transient interaction of LCRs of multiple RNA-
binding proteins. Phase separation also makes the protein vul-
nerable to aggregation and transition to pathology,[39a] although 
this transition was recently reported to be independent from stress 
granule formation.[65b,c] Most of the genetic mutations related to 
TDP-43 proteinopathies cluster in the LCR of TDP-43 and in-
crease its aggregation propensity[67] (Fig. 1). Proposed structural 
transitions resulting from specific disease-causing modifications 
or PTMs are discussed later in context of molecular mechanisms 
of TDP-43 aggregation.
in the nucleus, a step necessary for splicing regulation.[42,50b] 
Interestingly, a specific phosphorylation event within the NTD 
may function as a ‘switch’ regulating TDP-43 oligomerization 
in cells.[50b] In vitro, TDP-43 NTD binds to TG-rich sequences 
with a low affinity, a property that may stabilize the interaction of 
the full length protein to target RNAs.[42] However, the structural 
basis of the NTD interaction with nucleic acids and the poten-
tial cooperativity with RRMs currently remains to be elucidated. 
Further high-resolution structural studies are necessary to reveal 
the quaternary structure of physiological TDP-43 oligomers in 
the nucleic-acid bound state. Likewise, the molecular basis of 
oligomerization-dependent splicing function of TDP-43 has not 
been determined yet. 
Nucleic Acid Binding by TDP-43 Tandem RRMs
TDP-43 can bind to both DNA and RNA in a sequence-
specific fashion, predominantly to TG/UG-rich sequences and 
also to other targets that may vary in sequence.[51] The sequence-
specificity is conferred by the tandem RRMs that bind 3-4 UG 
repeats per TDP-43 molecule, as revealed by the first crystal 
structures of isolated RRM1[52] and RRM2[53] in complex with 
TG-harboring DNA oligos. However, the distinct cooperativ-
ity in RNA recognition was shown from the solution structure 
of tandem RRMs in complex with UG-rich RNA (Fig. 1).[25] 
Interestingly, the two RRMs are arranged in a manner that al-
lows the formation of a continuous RNA binding surface required 
for binding longer sequences compared to a single RRM domain 
(Fig. 1).[25] This mode of RNA binding is unique in comparison 
to other tandem RRMs[25,41] with only similarity to the CPEB 
family of RNA binding proteins.[54] However, the exact role of 
such RNA binding mode still remains unclear. One hypothesis 
is the potential organization of the NTD and the low complexity 
region (LCR) in a way that would favor homo- and hetero- mo-
lecular protein interactions.[25,42] The crystal structure of RRM1 
in complex with DNA suggests that RRM1 is crucial for nucleic 
acid recognition.[52] Indeed, mutation of Phe147 and Phe149 that 
comprise the canonical RNP2 and RNP1 motif of RRM1, respec-
tively, is sufficient to impair RNA binding of full-length TDP-
43. [52] Interestingly, point mutations of residues involved in RNA 
binding (Phe147 and Phe149 in RRM1, Phe229 and Phe231 in 
RRM2) lead to the formation of nuclear TDP-43-positive inclu-
sions,[30,55] in accordance with recent work suggesting that RNA 
binding prevents aggregation of TDP-43 and other RNA-binding 
proteins. [56] However, the nature of these inclusions does not 
resemble the pathological cytoplasmic aggregates seen in dis-
ease.[30] Nevertheless, any post-translational modification (PTM) 
close to the RNA binding interface may well trigger the forma-
tion of such inclusions, which may result in pathological aggre-
gation (discussed later). Indeed, acetylation of TDP-43 at Lys145 
and Lys192 (Fig. 2) alters RNA interactions[55b] and results in 
NTD RRM1





















Fig. 2. Post-translational modi-
fications of TDP-43. Various 
experimentally validated post-
translational modifications are de-
picted on the schematic structure 
of TDP-43, including acetylation 
on specific lysines (shown in 
green), sumoylation (magenta), 
phosphorylation (red), methylation 
(blue) and cleavage by caspase-3 
(depicted by red scissors).
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TDP-43 Proteinopathies
TDP-43 was first identified in 2006 as the major aggregated 
protein in the ubiquitinated and phosphorylated cytoplasmic in-
clusions found in the neurons of patients with ALS and FTD. [5] 
TDP-43-positive inclusions were subsequently found in the ma-
jority of ALS patients (97%), in both sporadic and familial cases 
(with the exceptions of SOD1-ALS and FUS-ALS).[4a] However, 
TDP-43 pathology is not restricted to ALS and FTD, but is also 
found in other neurodegenerative diseases, such ~25% of patients 
with Alzheimer’s disease, ~70% of patients with hippocampal 
sclerosis and in a small subset of cases with Lewy body disorders, 
Pick’s disease, corticobasal degeneration, agyrophilic grain dis-
ease and Huntington’s disease.[68] Interestingly, TDP-43-positive 
inclusions with different shapes are also a feature in all tested 
cases of the well-known ALS and Parkinsonism-dementia com-
plex (PDC) of unknown etiology in the Chamorro population of 
Guam.[69] Considering the above-mentioned studies, it is conceiv-
able that a combination of a particular proteinopathy in concert 
with TDP-43 pathology may result in a very specific clinical 
presentation. Neurodegenerative diseases linked to the primary 
deposition of both full-length and fragmented TDP-43 showing 
specific PTMs and detergent insolubility are collectively termed 
‘TDP-43 proteinopathies’.[5]
TDP-43 Loss of Function 
The relative contributions of the loss of function and gain of 
toxicity from TDP-43 to disease progression are still not fully 
elucidated. While TDP-43 cytoplasmic inclusions are a hallmark 
of TDP-43 proteinopathies, the aggregation of this protein and 
the regions it affects can vary across patients.[7] For example, a 
percentage of affected cells in FTLD and sporadic ALS patients 
do not display aggregates but rather show nuclear clearance with 
only diffuse cytoplasmic staining.[70] Such TDP-43 mislocaliza-
tion is thought to precede aggregation of the protein,[70a] and 
clearly demonstrates an early loss of TDP-43 function mecha-
nism operating in those affected cells. Being involved in diverse 
cellular processes, loss of TDP-43 is certainly detrimental to the 
cell, as shown by early lethality of TDP-43 homozygous knock-
out mice.[71]
Depletion of TDP-43 in cellular and animal models results 
in an overall alteration of RNA metabolism in ALS/FTD.[4a,22,27] 
TDP-43 targets some of the neuron-enriched long genes ex-
pressed in the human brain.[22a] Misregulated expression of these 
genes such as those encoding for neurexin 3 (NRXN3), parkin 
(PRKN) or progranulin (GRN) may be specifically detrimental to 
neurons than other cell types in the brain.[22a] Specifically, wide-
spread splicing alterations of direct and indirect TDP-43 targets 
have been reported in animal models and humans.[22] Most inter-
estingly, mouse models that showed abnormal splicing patterns of 
TDP-43 targets resulting from a partial loss of TDP-43 or from the 
expression of ALS-linked mutated TDP-43 developed ALS-like 
phenotypes lacking cytoplasmic inclusions.[72]
It is worth to remark that, among the targets of TDP-43, one 
can find the mRNAs encoding for other proteins that aggregate 
in different neurodegenerative disorders, such as FUS, amyloid 
precursor protein (APP), huntingtin, α-synuclein, progranulin 
and tau.[22a] TDP-43 controls either the levels or the splicing of 
these mRNAs.[22a] In fact, TDP-43 pathology has been observed 
in brains of patients suffering from Alzheimer’s disease and the 
aforementioned Guam-PDC, which present with tau neurofibril-
lary tangles as a characteristic feature.[68g,69a,b] It has recently 
been reported that TDP-43 controls the alternative splicing of tau 
and, when mutated, promotes the misregulation of the ratio of 
the two tau isoforms, an alteration seen in several tauopathies.[73] 
Furthermore, TDP-43 has also been shown to potentiate toxicity 
in dopaminergic neurons of transgenic mice, suggesting a syner-
gistic interplay between TDP-43 and α-synuclein.[74] Therefore, 
alterations in nuclear TDP-43 levels increases the risk of misregu-
lation of other proteins levels and isoforms in diseases.
Intriguingly, even though TDP-43 loss of function contributes 
to disease progression, the majority of cellular and animal models 
of TDP-43 have failed to fully recapitulate the ALS/FTD-TDP 
pathology.[72,75] Therefore, even though loss of TDP-43 function 
is a consistent feature in TDP-43 proteinopathies and suggests a 
direct involvement in the neuron phenotype, it alone cannot fully 
explain the disease progression in animal models of motor neuron 
disease.[4a]
Pathologic Assemblies of TDP-43 
TDP-43 aggregates are the main hallmark of TDP-43 pro-
teinopathies, yet the role in disease remains unclear. From protec-
tive structures that sequester potentially toxic misfolded proteins 
to composing the main toxic species, TDP-43 aggregates have 
even been suggested to represent an irrelevant structure that cor-
relates with the true toxic phenomenon.[76] All three possibilities 
are compatible with their presence in disease-affected neurons. 
TDP-43 aggregates display specific characteristics such as pre-
dominant cytoplasmic localization, proteolytic fragmentation 
and PTMs such as ubiquitination and phosphorylation (Fig. 2).[5] 
Although not as abundant, nuclear pTDP-43 inclusions have also 
been reported in patients with different types of familial FTD.[5,77] 
Currently, the molecular architecture of cytoplasmic patho-
logical TDP-43 assemblies is enigmatic and remains to be de-
termined at higher resolution. Most of the pathological TDP-43 
inclusions present with non-amyloidogenic features and concomi-
tantly do not show reactivity to amyloid specific dyes such as 
Congo red and thioflavin T and S, displaying instead a granular 
or amorphous non-filamentous morphology.[78] In line with these 
findings, bacterially expressed TDP-43 was reported to form 
amorphous aggregates in transmission electron or atomic force 
microscopy studies.[79] However, other studies have reported fila-
mentous TDP-43 structures in some patient brains[20b,80] and in a 
subset of ALS cases thin TDP-43 skein-like filaments in spinal 
motor neurons are positive to thioflavin S.[81] Furthermore, recom-
binant full-length TDP-43 has been reported to form amyloid-
like spherical oligomers as observed by transmission electron and 
atomic force microscopy, and said structures could be detected 
by an oligomer specific antibody in the FTLD brain tissues.[82] 
Moreover, recent studies reported polymorphic amyloid or labile 
amyloid-like structures formed by short synthetic TDP-43 frag-
ments residing within its RRM2,[83] and LCR.[61]
These contradictory results may potentially originate from dif-
ferences in protocols used to purify recombinant proteins, which 
may lead to heterogeneous preparations comprising a mixture of 
soluble oligomers, misfolded protein precipitates, disordered ag-
gregates or eventually specific ordered aggregates. Currently, it is 
difficult to determine which of these species bears resemblance 
(if any) to the pathological protein aggregates seen in patients. 
Isolation of aggregated pathological TDP-43 from brain tissue has 
been difficult due to its co-purification with physiological TDP-43 
and other RNA-binding proteins. Recently, a new method for en-
richment of pathological TDP-43 devoid from other physiologi-
cal interactors opened the door to detailed biochemical analysis 
of different TDP-43 assemblies isolated from patient samples. [84] 
Such a method may allow the high-resolution structural deter-
mination of patient-derived pathological TDP-43 assemblies. 
Moreover, it is likely that TDP-43 forms heterogeneous patholog-
ic assemblies within patient tissues, a notion strongly supported 
by the different morphology[85] and biochemical properties[84] of 
pathological TDP-43 assemblies from different disease subtypes, 
as well as the ability of TDP-43 segments to form polymorphic 
structures in vitro.[61,83] Pure isolation of pathological TDP-43 
from autopsy brain from patients with distinct FTLD subtypes al-
lowed the identification of large TDP-43 assemblies with distinct 
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mic compartments, these are independent from stress granules and 
are devoid of other proteins or RNA,[65b,c] while a contemporaneous 
study found that stress granule assembly can initiate ALS/FTD-like 
pathological TDP-43 inclusions in cells.[103] While this important 
point remains to be clarified, a likely scenario is that more than one 
pathway results in the formation in pathological assemblies and 
phase separation plays a key role in the process. 
TDP-43 Pathogenic Mechanisms – Transition from 
Physiological to Pathological State 
Early events leading to TDP-43 pathology, including nuclear 
clearance and cytoplasmic aggregation, remain unclear both in 
familial and sporadic cases. Since the majority of pathological 
aggregates identified in disease-affected neurons are localized in 
the cytoplasm, the transition from the physiological to the patho-
logical cytoplasmic aggregated state is potentially preceded by 
cytoplasmic mislocalization (Fig. 3).[70a] Here, we summarize our 
current understanding of the molecular basis of transitions from 
physiological to pathological state initially characterized by a 
misfolding event. Most of the mutations in familial cases of TDP-
43 proteinopathies are localized in the LCR (Fig. 1) and only a 
few mutations (A90V, P112H and D169G in Fig. 1)[90c,104] in the 
N-terminal half (aa 1-265), suggesting a conserved role of this 
region for protein function. The mutations have been proposed 
to induce misfolding and enhance aggregation propensity of the 
protein.[67] However, since most of TDP-43 proteinopathies are 
sporadic in nature, in the following section we focus on de novo 
mechanisms of TDP-43 aggregation.
TDP-43 NTD & LCR – Antagonist and Agonist of 
Pathological Aggregation?
The role of TDP-43 NTD in influencing pathological aggre-
gation remains controversial. Some studies suggest that since the 
NTD brings two TDP-43 molecules into proximity, this region 
must promote inclusion formation.[47b,105] However, recent bio-
chemical and cellular data points to a preventive role of NTD-
mediated dynamic oligomerization in irreversible protein aggre-
gation.[42] Indeed, NTD-mediated interactions should potentially 
bring various TDP-43 molecules together to enhance aggrega-
tion. However, due to lack of high-resolution structural data on 
full-length protein, it is difficult to predict the positions of the 
LCRs relative to the other domains in TDP-43 protein–RNA 
oligomers. Structural analysis of full-length protein in complex 
with  nucleic acids is indispensable to determine the dynamics 
and spatial organization of TDP-43 LCR’s. In vitro, recombinant 
TDP-43 LCR in isolation shows a minor population displaying 
transient inter-molecular interactions in the α-helical region of 
TDP-43.[59c] However, it is not clear if a similar interaction oc-
curs in vivo in the context of full-length protein in complex with 
nucleic  acids. The cellular data using GFP complementation show 
that the NTD-mediated interactions spatially separate the LCRs of 
TDP-43 impeding their interaction.[42,106] Therefore, the dynamic 
NTD-mediated intermolecular interactions in complex with nu-
cleic acids potentially prevent its aggregation.[42] This observation 
is further supported by subsequent independent studies, which 
show that either deletion of NTD[73] or dimerization-impaired[107] 
TDP-43 increases inclusion formation in cells suggesting its pro-
tective role in preventing aggregation in healthy state. A different 
approach reported that oligomerization disruption by a specific 
phosphorylation event within the NTD reduces TDP-43 liquid–
liquid phase separation in vitro and in cells.[50b] Therefore, any 
factor altering TDP-43 oligomerization and/or nucleic acid bind-
ing would destabilize native TDP-43 oligomers (Fig. 3), thereby 
disturbing the equilibrium between the nuclear oligomeric and 
monomeric TDP-43, which may result in cytoplasmic mislocal-
ization due to passive diffusion.[35,45] Below we summarize various 
mechanisms that might potentially alter this native equilibrium.
features, including size, density, shape, proteolytic resistance and 
ubiquitination.[84] Importantly, these isolated TDP-43 assemblies 
also showed distinct neurotoxicity and seeding ability, which cor-
related with the disease duration of the patients they originated 
from, suggesting that the molecular pathologic TDP-43 signature 
may determine specific clinical characteristics.[84]
Various proteolytic fragments have been reported to be present 
in the pathologic inclusions in addition to the full-length TDP-
43. [5,86] The first fragments identified in FTLD patients were TDP-
43 C-terminal ends of ~25 kDa and ~35 kDa in size, which were 
termed CTF25 and CTF35, respectively.[5,87] These fragments are 
thought to occur by cleavage of TDP-43 by caspase-3 and -7[87,88] 
(Fig. 2). However, the advancement of proteomic methods has al-
lowed the identification and characterization of other C-terminal 
TDP-43 fragments produced by other proteases in ALS and 
FTLD. [86,89] Interestingly, several mutations in TDP-43 known to 
cause ALS have been linked to an alteration in the proteolytic 
pattern of TDP-43 in vitro, in cellular models and in patients.[8,90] 
Proteolysis of TDP-43 results in truncated fragments lacking the 
NLS and at least one RNA binding domain, which results in the 
loss of function and localization of the fragmented protein into 
the cytoplasm.[88a] Moreover, these mislocalized fragments con-
taining the LCR have a higher propensity to form aggregates,[88a] 
which can drive the sequestration of full-length TDP-43, leading 
to the decrease of its functional pool.[91] 
Pathologic TDP-43 aggregates further adopt other PTMs such 
as phosphorylation,[5] ubiquitination,[5] sumoylation[92] and acety-
lation.[55b] TDP-43 phosphorylation at serines 379, 403, 404, 409 
and 410 is the best studied disease-associated PTM of TDP-43 and 
is exclusively labeling pathological species (Fig. 2).[5,77b] Casein 
kinase 1 (CK1) has been implicated in TDP-43 phosphorylation in 
patients[93] and CK1 levels are elevated in neurons with pTDP-43, 
potentially via a regulatory loop in which TDP-43 binds and regu-
lates CSNK1 mRNA levels and CK1 in turn directly phosphory-
lates TDP-43.[93b] While TDP-43 phosphorylation is a useful 
pathological mark, its role in the disease process remains unclear. 
Nevertheless, several lines of evidence suggest that phosphoryla-
tion modulates TDP-43 aggregation and toxicity. CK1 was shown 
to directly phosphorylate TDP-43 in cellular models[77b,94] and to 
enhance toxicity of ALS-linked TDP-43 mutants in a Drosophila 
model.[95] In line with this, pTDP-43 has been shown to persist 
longer and to exhibit greater insolubility than unmodified TDP-
43 in cells.[96] Blocking phosphorylation via mutating serines 409 
and 410 to alanines alleviate aggregation in cells[97] and the same 
mutations were shown to mitigate neurotoxicity in C. elegans,[98] 
collectively indicating that phosphorylation is a critical step in 
the maturation and toxicity of pathological TDP-43 assemblies.
The mechanism of pathological TDP-43 toxicity remains un-
known, but it has been hypothesized that sequestration of other 
proteins and/or cellular RNA may contribute to toxicity. This was 
supported by the idea that TDP-43 aggregates evolve gradually 
from physiological stress granules, containing multiple RNA bind-
ing proteins and RNAs, some of which might remain trapped in the 
pathological assemblies. Supporting this view, in cellular models 
TDP-43 aggregates have been shown to sequester other proteins, 
especially RBPs and stress granule markers, such as TIA-1, TIAR 
and PABP.[64,99] Yet, the evidence from human brain is less conclu-
sive. The majority of hnRNPs were not found to co-localize with 
TDP-43-positive inclusions,[100] although some reports suggest co-
aggregation of specific candidate RNA binding proteins, includ-
ing TIA-1 and eIF3,[99a] (Poly-A binding protein-1) PABP1 in FTD 
patients with C9orf72 mutations[101] and hnRNP E2 in semantic 
dementia but not in other TDP-43 proteinopathies.[102] Our more re-
cent unbiased approach using mass spectrometry on biochemically 
isolated TDP-43 aggregates did not reveal any stress granule pro-
teins.[84] In line with this, two latest studies showed that, while TDP-
43 aggregates in cells indeed evolve from phase separated cytoplas-
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the production of CTF25.[90b] Cleavage of TDP-43 within RRM2 
removes the NTD and therefore disrupts functional and dynam-
ic interactions.[42] It was reported that the two β-strands within 
RRM2 – β3 and β5 are prone to fibril formation similar to amy-
loids.[111] The proteolytic cleavage within RRM2 domain would 
expose this region for fibril formation.[111] On the other hand, the 
A90V mutation is present adjacent to the NTD in the linker region 
harboring the NLS and caspase-3 cleavage site. Such a mutation 
may potentially either alter the protein localization or its ability 
to be cleaved by caspase-3.[90a] Mass spectrometry of pathological 
inclusions in ALS have revealed additional cleaved fragments of 
TDP-43 corresponding to different unreported cleavage sites,[86] 
strengthening the hypothesis of TDP-43 cleavage in mislocaliza-
tion and initiation of aggregate formation in the cytoplasm. 
Environmental Stressors 
The amino acid sequence of TDP-43 contains six cysteine res-
idues, two of which are located in the NTD (Cys39 and Cys50), 
while the other four are located in the RRMs (Cys173, Cys175, 
Cys198 and Cys244). Based on the structures of isolated TDP-43 
domains, no inter- or intra-molecular disulphide bonds have been 
identified in the native state.[25,42] In this folded state, Cys39 and 
Cys50 are surface exposed but do not engage in disulphide bond 
formation in vitro.[42] Moreover, from the structure of TDP-43 
RRMs in complex with RNA, it is known that the four cysteines 
Altered Equilibrium between Physiological States 
Splicing alterations have been reported to increase the expres-
sion levels of a truncated isoform of TDP-43 in ALS patients,[108] 
resulting from usage of the alternative start codon ATGMet85, which 
leads to the deletion of 91 bp in exon 2. This isoform decodes a 
protein lacking the extreme NTD that is important for mediat-
ing the nuclear dynamic protein oligomerization,[42,106] and shows 
enhanced cytoplasmic localization due to lack of one region of 
the bipartite NLS.[108] This truncated protein has increased insolu-
bility compared to full-length TDP-43 and was shown to form 
inclusions in ALS patients.[108] This mechanism highlights the im-
portance of either expression of truncated protein or proteolytic 
cleavage resulting in similar fragments mislocalized to the cyto-
plasm as an early event in the formation of pathologic aggregates 
(Fig. 3). TDP-43 has multiple predicted caspase-3 and calpain 
cleavage sites.[90a] Specific cell signaling triggered by brain trau-
ma events may result in the activation of these proteases resulting 
in TDP-43 cleavage.[109] Such signaling events may differ in each 
disease subtype that may result in a characteristic cleavage pattern 
that is often associated with them. Caspase-3 activity has been 
linked to the levels of progranulin,[87] whose mutation itself also 
increases the risk of developing FTD.[110] As indicated before, ge-
netic mutations in TDP-43 also alter its proteolytic susceptibility. 
D169G mutation in RRM2 increases the thermal stability of the 


































































Fig. 3. Molecular mechanisms of TDP-43 aggregation. In the healthy state, the majority of TDP-43 is in the nucleus where it forms functional and 
dynamic oligomers. This functional TDP-43 maintains its own steady state levels via an autoregulatory mechanism and in turn regulates the normal 
RNA homeostasis of the cell. However, various events may initiate the pathologic cascade that may independently or in concert result in pathologic 
aggregation of TDP-43. Altered RNA splicing (1), TDP-43 misfolding due to environmental factors (2,3) or specific PTMs (4) and stress (5) may lead 
to pathologic aggregation of TDP-43. Some of these events (1,2,3) may induce cytoplasmic mislocalization. As TDP-43 translocates to the cytosol, 
there may be specific regions with high TDP-43 concentration that can lead to phase separation via its low complexity region. Such droplets may be 
the precursors of the mature pathological aggregates seen in disease. Moreover, mutations in protein degradation pathways (6) enhance the accu-
mulation of these pathologic aggregates.
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in the RRMs are buried in the core of the RRMs[25] and would po-
tentially not engage in disulphide bond formation unless the pro-
tein is misfolded. Interestingly, no cysteine mutations have been 
reported so far in ALS/FTD. However, upon oxidative stress, full 
length TDP-43 is mislocalized from the nucleus to the cytosol 
and forms large aggregates in addition to small oligomers (Fig. 
3).[112] Oxidative stress in the cytosol can induce the formation of 
inter-molecular disulphide bonds.[112a] Studies on the aggregation 
process have shown that oxidation of cysteines located in the two 
RRMs decreases protein solubility, leading to the formation of 
intra and inter-molecular disulphide linkage,[112a,113] and that cys-
teine residues in RRM1 direct the conformation of TDP-43. [114] 
Similarly, induced intermolecular disulphide bonds in RRM2 
show increased aggregation behaviour.[115] Such disulphide-
linked TDP-43 multimers have also been detected in a transgenic 
mouse model of TDP-43 harbouring the A315T mutation.[116] 
Intriguingly, interaction of zinc ions with the two RRMs of TDP-
43 occurs with micromolar affinity and triggers structural modifi-
cations that decrease its thermostability,[117] potentially leading to 
intracellular aggregation of TDP-43.[118]
Other Genetic F actors
Apart from TDP-43, mutations in many other genes have been 
identified to cause TDP-43 proteinopathies. These mutations ei-
ther belong to genes involved in the RNA processing pathway 
or in protein degradation pathways.[4a,67] In the former category, 
mutations in genes such as MATR3,[13] hnRNPA1,[14] TIA1[119] 
and C9ORF72[15,120] lead to diverse alterations in RNA process-
ing events. Moreover, a hexanucleotide expansion mutation in 
C9ORF72 also leads to expression of dipeptide repeat proteins 
(DPRs), which have been shown to interact with TDP-43 via the 
LCR[121] and to impair TDP-43 import into the nucleus.[122] In 
the latter category, included are genes like VCP, UBQLN2 and 
SQSTM1 involved in the UPS or in autophagy, both of which help 
maintain protein homeostasis.[67] Indeed, these pathways are in 
charge of eliminating misfolded proteins or protein aggregates, 
respectively. What determines the occurrence of TDP-43 patholo-
gy in multiple neurodegenerative diseases and why other hnRNPs 
with significant structural and functional similarity to TDP-43 
are less frequently transformed to pathogenic entities remains 
unknown. Nevertheless, this predominance of TDP-43 pathology 
is intriguing and makes it one of the most suited therapeutic and 
diagnostic targets for various neurodegenerative diseases.
Challenges in Therapeutics & Diagnostics
Currently, a major challenge in TDP-43 proteinopathies is the 
distinction between functional and pathological states of TDP-
43. This is complicated by the fact that pathological states may 
be very diverse depending on the specific disease subtype.[7,84,85] 
It remains unclear which of the pathological TDP-43 species are 
toxic and which may represent the end result of a pathogenic path-
way. Indeed, similar to α-synuclein,[123] small oligomers may rep-
resent the toxic species that are primarily responsible for disease 
progression and spread of pathology. This highlights the need for 
high-resolution structural determination of all physiological and 
pathological states of TDP-43 and mapping of structure-func-
tion-toxicity relationships. This is essential for the development 
of diagnostic tools to enable both early diagnosis, but also the 
monitoring of disease progression that will permit evaluation of 
disease-modifying therapeutics. Structural transitions triggering 
misfolding, mislocalization and aggregation of TDP-43 must be 
characterized at the molecular level for a rational design of di-
agnostic and therapeutic agents. Moreover, pathological TDP-43 
species were shown to seed aggregation and trigger toxicity in 
cellular[65b,84,124] and animal[125] models. The molecular and cellu-
lar determinants of this important mechanism that likely underlies 
spreading and propagation of TDP-43 pathology within a patient’s 
nervous system[126] urgently needs to be elucidated, as it may lead 
to the identification of new molecular targets for therapeutic in-
terventions to treat these devastating diseases. 
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